Yanfei Yang

Yanfei Yang joined Flagship Pioneering in 2024 as Associate Director of Translational Sciences for Pioneering Medicines. In this role, she is responsible for translational strategies and capability building for Pioneering Medicines’ cross-functional programs with a primary focus at the cardiorenal therapeutic area.

As a translational scientist, Yanfei brings over 17 years of combined academic and industry experience in drug discovery and development. Previously, she worked at CRISPR Therapeutics, leading both CRISPR/AAV platform development studies and CRISPR application in therapeutic area projects from target identification to IND-enabling studies with increasing responsibilities. Prior to CRISPR, she was a postdoctoral fellow at Brigham and Women’s Hospital-Harvard Medical School, where she discovered novel molecular mechanisms underlying cardiac regeneration and earned the Best Manuscript Award from the American Heart Association.

Yanfei has over a decade of training and research experience in cardiovascular diseases, and has worked across various therapeutic areas, including muscular dystrophy, neuronal pain, liver diseases, hypertension, and metabolic diseases. She holds four patents and has co-authored over a dozen publications.

Yanfei received her PhD in Molecular and Cellular Biology from Rutgers University, where she investigated noncoding RNAs, antioxidants, and Hippo pathways in cardiomyocyte growth and survival.